Navigation Links
MacroGenics Raises $25M in Series D-2 Financing
Date:9/25/2008

Proceeds to be Used for Advancement of Cancer Stem Cells and Other

Development Programs

ROCKVILLE, Md., Sept. 25 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it has raised $25 million in a Series D-2 financing. The round, led by Nextech Venture, included additional new investors Arcus Ventures, Innovis Investments and Eli Lilly and Company. Also participating in the financing were existing investors Alexandria Real Estate, Alta Partners, CIDC, InterWest Partners, Mitsubishi UFJ, OrbiMed Advisors, Red Abbey Venture Partners, RiverVest, Texas Pacific Group Ventures and Ventures West.

MacroGenics expects to use the proceeds from this financing to fund the cancer stem cell program it acquired through its acquisition of Raven Biotechnologies in July. In addition, the proceeds will be used to further advance the company's autoimmune, cancer and infectious disease product candidate portfolio, as well as for general working capital purposes. MacroGenics' most advanced product candidate is teplizumab, which is being developed in partnership with Eli Lilly and Company. Teplizumab is currently being studied in the PROTEGE trial, a global pivotal Phase II/III clinical trial for individuals with recent-onset type 1 diabetes.

"We are delighted to add Nextech Venture, Arcus Ventures and Innovis Investments, three oncology-focused investors, as well as Eli Lilly and Company to our roster of blue chip shareholders. Our experienced investor syndicate provides critical support to MacroGenics as we drive our programs through clinical development towards commercialization," commented Dr. Scott Koenig, President and CEO of MacroGenics. "In addition, with the recent acquisition of Raven Biotechnologies and the addition of their exciting technologies to our own platforms, we are planning
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MacroGenics Acquires Raven Biotechnologies
2. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
3. Yongye Biotechnology International Raises $9.4 Million in Private Placement
4. Proteolix Raises $79 Million in Series C Financing
5. Bacon Eating Contest Raises Money for American Heart Association
6. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
7. Pacific Biosciences Raises $100 Million to Fund Commercial Product Development
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. BSP Raises $2.6 Million Dollars From Private Investors
10. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
11. Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  The Dr. Samadi Prostate Cancer ... now offering a full suite of new genetic testing methods ... biopsy, for diagnosing prostate cancer. Dr. ... genetic tests for assessing the risk and optimizing the diagnosis ... "We,re very excited to now offer these revolutionary genetic tests ...
(Date:6/29/2015)... --  Pharnext SAS today announced that data related to ... Charcot-Marie-Tooth Type 1A (CMT1A), is being presented in four posters ... (PNS) Biennial Meeting at the Quebec Congress Center in ... 2, 2015. At Poster Viewing Session 4, four ... 7p.m. EDT: Poster 23: "A Meta-Analysis Of ...
(Date:6/29/2015)... 29, 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... Petit, has been awarded the Lifetime Achievement Award in ... The Entrepreneur Of The Year Program, ...
(Date:6/29/2015)...   For the seventh year running, Across Health conducted ... digital maturity called the Multichannel Maturometer . The ... maturing fast enough. While it,s true that technology is ... and customers are increasingly "digital natives", pharma still lags ... ...
Breaking Biology Technology:New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4
... BEACH, Calif., Jan. 4, 2011 Genesis Biopharma, Inc. ... company developing targeted cancer therapies, today announced that it ... to which it entered into definitive agreements with accredited ... the Genesis Biopharma common stock for a purchase price ...
... Va., Jan. 3, 2011 BNA Books , a ... Second Edition of ... that provides an in-depth consideration of the entire body of ... (Logo: http://photos.prnewswire.com/prnh/20090529/DC24463LOGO )   ...
... a clinical-stage regenerative medicine company developing novel therapies ... and Drug Administration (FDA) authorized commencement of a ... safety of its lead product, JVS-100, for the ... Stromal-cell Derived Factor 1 (SDF-1), which has been ...
Cached Biology Technology:Genesis Biopharma Raises $845,000 in Private Financings 2New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 2New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 3New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 4Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia 2Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia 3
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... Systems market, over the next six years. It contains ... affect the industry, along with their impact from the ... It also discusses the industry, market, and technology ... expected that the need of concerned authorities to efficiently ...
(Date:6/23/2015)... MINNETONKA, Minn. , June 23, 2015 /PRNewswire/ ... technology company that supports the entire spectrum of ... iMedNet ™ , the company,s ... has been awarded a Silver 2015 Stevie® Award ... the Health Products & Services Website category.  The ...
(Date:6/18/2015)... NEW YORK , June 18, 2015 ... in US$ Million by the following Product Segments, which ... Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and ... for the US, Canada , ... Asia-Pacific , Latin America ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... Bloomberg School of Public Health has received $28 million ... the David and Lucile Packard Foundation and the William ... Advance Family Planning advocacy initiative within the Bloomberg School,s ... Health. Advance Family Planning aims to increase ...
... PHILADELPHIAResearchers at the Kimmel Cancer Center at Jefferson (KCC) ... have developed potentially game-changing diagnostic and prognostic genetic tests ... distinguish clinically-relevant cancers. The team, led ... of the KCC and the Chair of the ...
... functional body: as embryos develop and grow, they must form ... the embryo. The exact mechanism underlying this fundamental characteristic, called ... EMBL Heidelberg is now one step closer to understanding it. ... a mouse embryo is controlled by how the expression of ...
Cached Biology News:Bloomberg School receives $28 million for family planning advocacy 2Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson 2Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson 3Sync to grow 2
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Biology Products: